# Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

> **NCT02757105** · PHASE2 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 127 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** BEKINDA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02757105
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-19
- **Primary completion:** 2017-06-16
- **Final completion:** 2017-07-14
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757105, "Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02757105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*